Every 10-Q that Femasys Inc. (FEMY) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow FEMY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FEMY filings page.
Femasys Inc. reported continued operating losses while significantly strengthening its balance sheet through post‑quarter financing. For the six months ended June 30, 2026, sales were $756,716, roughly flat versus 2025, but second‑quarter sales fell 18.9% year over year to $331,827, mainly from lower international FemVue sales. Operating expenses for the quarter rose 28.1% to $5.3 million, driven by higher research and development, sales and marketing, and general and administrative spending as the company advances FemBloc and commercializes FemaSeed and related products.
Loss from operations was $9.3 million for the first half, similar to 2025, but the net loss narrowed sharply to $3.6 million from $10.5 million, primarily due to non‑cash gains of $5.96 million from remeasuring and then reclassifying the conversion option and warrant liabilities on the 2025 convertible notes to equity. Cash and cash equivalents declined to $1.44 million from $9.27 million at year‑end, reflecting $8.1 million of operating cash outflows and modest ATM and ESPP equity issuance.
After quarter‑end, Femasys completed a private placement of common stock and pre‑funded warrants expected to generate about $30 million of gross proceeds, with additional potential proceeds from three‑year warrants. Management states that, including this financing, liquidity is sufficient for at least 12 months. In June 2026 the company also effected a 1‑for‑20 reverse stock split to comply with Nasdaq listing requirements.
Femasys Inc. reported net income of $846,100 for the quarter ended March 31, 2026, compared with a net loss a year earlier. Sales rose to $424,889, driven mainly by FemVue, while operating expenses were $4,489,816, reflecting higher sales and marketing but sharply lower research and development spending.
The company’s profit was primarily due to $5,069,633 of other income, including large non‑cash gains from changes in the fair value of its convertible note conversion option and warrant liabilities. Cash and cash equivalents fell to $5,386,041 after $4,143,508 of cash used in operating activities, and the accumulated deficit reached $144,980,044.
Management states that existing cash, expected product revenue and current facilities are only sufficient to fund operations into the third quarter of 2026, and that substantial doubt exists about Femasys’ ability to continue as a going concern without additional financing. The company highlights significant potential dilution from outstanding convertible notes and multiple warrant series as it pursues commercialization of its women’s health portfolio and the pivotal FemBloc trial.
Femasys Inc. reported results for the quarter ended June 30, 2025. Quarterly sales rose to $409,268 (six months $750,532), driven by increased FemaSeed and FemVue sales. The company recorded a net loss of $(4,585,922) for the quarter and $(10,482,761) for the six months, with six-month net loss per share of $(0.39). Cash and cash equivalents were $3,218,067, total assets $13,780,409, total liabilities $12,272,974, and an accumulated deficit of $137,681,018. Inventory increased to $5,232,738.
The filing highlights regulatory and commercial milestones: CE mark certification under EU MDR for the FemBloc delivery system (March 2025) and for the class III blended polymer component (June 2025), strategic distribution in Spain, enrollment of the U.S. pivotal trial, and subsequent commercial and regulatory updates including an approximate $400,000 order in Spain and Australia/New Zealand approvals announced July 1, 2025. Financing activity included at-the-market sales (~$5.5M in H1 2025) and a June 2025 underwritten offering (gross $4.51M, net proceeds $3.705M). Management states substantial doubt exists about the company’s ability to continue as a going concern and discloses Nasdaq non-compliance notices with deadlines to regain compliance.